PEPFAR Reauthorization: Side-by-Side of Legislation Over Time
This brief identifies time-bound PEPFAR authorities and also provides a detailed side-by-side comparison of PEPFAR’s authorizing legislation over time.
Read More
GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH
Results from the Phase 3 DREAMM-7 study show GSK drug Blenrep is helping multiple myeloma patients live longer compared to treatment with blockbuster Johnson & Johnson drug Darzalex. The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to…
How CRISP Shared Services Is Approaching Public Health Data Modernization
The HIE infrastructure organization’s Sheena Patel, M.D., describes setting up an Implementation Center as part of a CDC program
5 Key Facts About Children with Special Health Care Needs and Medicaid
Amid debates about proposed cuts to federal Medicaid spending, this brief analyzes key characteristics of children with special health care needs and explores how Medicaid provides them with coverage.
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim
ArriVent Biopharma claims best-in-class potential in gastrointestinal cancers for its new asset, but it’s not specifying the class. It’s possible the Phase 1-ready drug goes after claudin 18.2, a hot target for GI cancer drug research that recently welcomed its first FDA-approved therapy and is in pursuit by several companies. The post Cancer Biotech ArriVent…
4 Things Startups Must Know to Achieve a Successful Tech Pilot
In recent years, providers have been increasingly conducting tech pilots to see which solutions can best improve their clinical and operation success. During a panel at MedCity News’ INVEST Digital Health conference in Dallas, healthcare leaders shared their insight on how startups can best serve their provider partners during these pilots. The post 4 Things…
Q&A: Christopher Stanley, M.D., M.B.A., of Henry Ford Subsidiary Populance
Nonprofit population health services company starts with internal customers but plans to expand
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. But Neurogene is able to avoid a lengthy clinical trial pause largely because of its participation in an FDA pilot program intended to speed up the development of therapies for rare diseases. The post Patient Dies in Gene Therapy…
THCB Gang Episode 140, Friday October 4
OK we are really back.! Following last weeks special with the Women Healthcare Leaders for Progress, the “regular” THCBGang is coming back for the Fall, mostly but not always at the 1pm PT 4pm ET timeslot on Thursdays. Joining Matthew Holt (@boltyboy) on #THCBGang on Friday October 4 at 1pm PST 4pm EST are futurist…